Hyloris Pharmaceuticals SA (ENXTBR: HYL)
Health Care · Pharmaceuticals · BE
€4.39
-2.44% today · -32.0% 1Y
Hyloris Pharmaceuticals SA (ENXTBR: HYL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $147.10M and employs 55 people.
Over the last twelve months the share price has lost 32.0%, trading between 4.20 and 8.40.
Tweenvest scores Hyloris Pharmaceuticals SA across four factors: quality 35/100, value 51/100, growth 100/100. Its strongest factor is growth.
HYL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $147.10M
- Revenue (TTM)
- $9.32M
- P/E
- —
- EPS
- -0.23
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- €8.40
- 52-week low
- €4.20
- Avg volume (3M)
- —
- Shares outstanding
- 28.00M
- Employees
- 55
- Next earnings
- —
About Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
- ISIN
- BE0974363955
- Founded
- 2012
- Listed since
- Jun 29, 2020
- Exchange
- Euronext Brussels
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,226.58 | -0.57% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.58 | -0.57% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.77% |
Figures last refreshed Aug 18, 2026.